YP
CRBP icon

Yellowstone Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Yellowstone Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$109K Hold
511
– – 0.06% 176
2017
Q3 		$110K Buy
+511
New +$100K 0.06% 197
2016
Q3 		$108K Sell
531
-922
-63% -$115K 0.04% 226
2016
Q2 		$130K Hold
1,453
– – 0.06% 196
2016
Q1 		$79K Buy
+1,453
New +$64.1K 0.03% 211

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Yellowstone Partners's CRBP Position: Q4 2017 in Review

Yellowstone Partners held its Corbus Pharmaceuticals (CRBP) position steady in Q4 2017 at 511 shares worth $109K. The position accounts for 0.06% of the portfolio, ranked #176.

Yellowstone Partners first reported a position in CRBP in Q1 2016 and has held it in 5 quarters since. The position peaked at $130K in Q2 2016. 88 funds tracked by Wall St. Rank hold CRBP as of Q4 2017.

  • Yellowstone Partners held 511 shares of Corbus Pharmaceuticals worth $109K as of Q4 2017.
  • Yellowstone Partners left its Corbus Pharmaceuticals share count unchanged in Q4 2017.
  • Corbus Pharmaceuticals made up 0.06% of Yellowstone Partners's portfolio in Q4 2017, its #176 holding.
  • Yellowstone Partners first reported a position in Corbus Pharmaceuticals in Q1 2016 and has held it in 5 quarters since.
  • Yellowstone Partners's Corbus Pharmaceuticals position peaked at $130K in Q2 2016.
  • 88 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2017.

Based on Yellowstone Partners's 13F filing for Q4 2017, filed 24 Jan 2018.